Guidelines for diagnosing and treating thrombotic thrombocytopenic purpura (TTP)
The International Society on Thrombosis and Haemostasis (ISTH) published guidelines are the first comprehensive, evidence-based, international guidelines on the diagnosis, treatment, and management of TTP.1
Most recent publication
The ISTH Guidelines for Diagnosis and Treatment were published July 2020.
With more than 5000 members across 100 countries, the ISTH is the leading thrombosis and hemostasis–related professional organization in the world.2.
Why the ISTH Guidelines were developed
Diagnosing and treating TTP can be complicated.1
○Rare disease, seen infrequently
○Signs and symptoms overlap with those of other TMAs and critical disorders with different treatment needs
○Acute onset and high mortality
○Rapid diagnosis is critical to minimize risk of mortality and long-term sequelae
○ADAMTS13 testing is not always available
•Management of TTP varies among healthcare professionals (HCPs)
•Treatment recommendations in TTP have evolved
ISTH created the guidelines as a comprehensive, uniform, international resource to inform the diagnosis and management of TTP1
The ISTH Guidelines can aid HCPs—both those with limited experience with TTP and those considered experts in TTP—in making a TTP diagnosis and following an appropriate treatment strategy.
• Emergency/critical care physicians
• Transfusion medicine specialists
• Policy makers
The ISTH has created the first evidence-based guidelines to support rapid TTP diagnosis and treatment.
ADAMTS13=a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13.
References: 1. Zheng XL, Vesely SK, Cataland SR, et al. ISTH Guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2486-2495. doi:10.1111/jth.15006 2. ISTH History. International Society on Thrombosis and Haemostasis website. Accessed November 16, 2021. http://www.ISTH.org/page/History